126 related articles for article (PubMed ID: 35718565)
1. Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer.
Campbell R; Costa DSJ; Stockler MR; Lee YC; Ledermann JA; Berton D; Sehouli J; Roncolato FT; Connell RO; Okamoto A; Bryce J; Oza AM; Avall-Lundqvist E; Berek JS; Lanceley A; Joly F; Hilpert F; Feeney A; Kaminsky MC; Diamante K; Friedlander ML; King MT;
Gynecol Oncol; 2022 Aug; 166(2):254-262. PubMed ID: 35718565
[TBL] [Abstract][Full Text] [Related]
2. Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer.
King MT; Stockler MR; O'Connell RL; Buizen L; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Bryce J; Donnellan P; Oza A; Avall-Lundqvist E; Berek JS; Sehouli J; Feeney A; Berton-Rigaud D; Costa DSJ; Friedlander ML;
Qual Life Res; 2018 Jan; 27(1):59-74. PubMed ID: 29248998
[TBL] [Abstract][Full Text] [Related]
3. Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study.
Lee YC; King MT; O'Connell RL; Lanceley A; Joly F; Hilpert F; Davis A; Roncolato FT; Okamoto A; Bryce J; Donnellan P; Oza AM; Avall-Lundqvist E; Berek JS; Ledermann JA; Berton D; Sehouli J; Feeney A; Kaminsky MC; Diamante K; Stockler MR; Friedlander ML;
Int J Gynecol Cancer; 2022 Jun; 32(6):761-768. PubMed ID: 35086926
[TBL] [Abstract][Full Text] [Related]
4. Development of the measure of ovarian symptoms and treatment concerns: aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer.
King MT; Stockler MR; Butow P; O'Connell R; Voysey M; Oza AM; Gillies K; Donovan HS; Mercieca-Bebber R; Martyn J; Sjoquist K; Friedlander ML
Int J Gynecol Cancer; 2014 Jun; 24(5):865-73. PubMed ID: 24844220
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of the measure of ovarian symptoms and treatment concerns for surveillance (MOST-S26): An instrument to complement the clinical follow-up of women with ovarian cancer after completion of first-line treatment.
Campbell R; King MT; Ross TL; Cohen PA; Friedlander ML; Webb PM
Gynecol Oncol; 2021 Nov; 163(2):398-407. PubMed ID: 34481610
[TBL] [Abstract][Full Text] [Related]
7. Effect of cancer stage on health-related quality of life of patients with epithelial ovarian cancer.
Techata A; Muangmool T; Wongpakaran N; Charoenkwan K
J Obstet Gynaecol; 2022 Jan; 42(1):139-145. PubMed ID: 33938358
[TBL] [Abstract][Full Text] [Related]
8. Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer.
Musoro JZ; Coens C; Greimel E; King MT; Sprangers MAG; Nordin A; van Dorst EBL; Groenvold M; Cocks K; Velikova G; Flechtner HH; Bottomley A;
Gynecol Oncol; 2020 Nov; 159(2):515-521. PubMed ID: 32972782
[TBL] [Abstract][Full Text] [Related]
9. Validation of the Mexican-Spanish Version of the EORTC QLQ-OV28 Instrument for the Assessment of Quality of Life in Women with Ovarian Cancer.
Gallardo-Rincón D; Toledo-Leyva A; Bahena-González A; Montes-Servín E; Muñoz-Montaño W; Coronel-Martínez J; Oñate-Ocaña LF
Arch Med Res; 2020 Oct; 51(7):690-699. PubMed ID: 32768148
[TBL] [Abstract][Full Text] [Related]
10. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer.
Greimel E; Bottomley A; Cull A; Waldenstrom AC; Arraras J; Chauvenet L; Holzner B; Kuljanic K; Lebrec J; D'haese S;
Eur J Cancer; 2003 Jul; 39(10):1402-8. PubMed ID: 12826043
[TBL] [Abstract][Full Text] [Related]
11. Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy - The GCIG symptom benefit study (SBS).
Roncolato FT; O'Connell RL; Joly F; Lanceley A; Hilpert F; Buizen L; Okamoto A; Aotani E; Salutari V; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Fehm T; Ledermann J; Roemer-Becuwe C; Stockler MR; King MT; Friedlander ML
Gynecol Oncol; 2020 Jan; 156(1):45-53. PubMed ID: 31836184
[TBL] [Abstract][Full Text] [Related]
12. A Comparative Analysis of Quality of Life in Women Diagnosed with Breast and Ovarian Cancer.
Słoniewski R; Dąbrowska-Bender M; Religioni U; Fronczak A; Staniszewska A; Duda-Zalewska A; Milewska M; Kędzierska M; Matkowski RA; Dykowska G; Słoniewska A; Kupiecka A
Int J Environ Res Public Health; 2022 May; 19(11):. PubMed ID: 35682288
[TBL] [Abstract][Full Text] [Related]
13. A study of symptoms described by ovarian cancer survivors.
Stavraka C; Ford A; Ghaem-Maghami S; Crook T; Agarwal R; Gabra H; Blagden S
Gynecol Oncol; 2012 Apr; 125(1):59-64. PubMed ID: 22155797
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: results from the population-based PROFILES registry.
Ezendam NP; Pijlman B; Bhugwandass C; Pruijt JF; Mols F; Vos MC; Pijnenborg JM; van de Poll-Franse LV
Gynecol Oncol; 2014 Dec; 135(3):510-7. PubMed ID: 25281491
[TBL] [Abstract][Full Text] [Related]
15. Association of financial status and the quality of life in Chinese women with recurrent ovarian cancer.
Shao Z; Zhu T; Zhang P; Wen Q; Li D; Wang S
Health Qual Life Outcomes; 2017 Jul; 15(1):144. PubMed ID: 28716032
[TBL] [Abstract][Full Text] [Related]
16. Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer.
Osoba D; Zee B; Pater J; Warr D; Kaizer L; Latreille J
Qual Life Res; 1994 Oct; 3(5):353-64. PubMed ID: 7841968
[TBL] [Abstract][Full Text] [Related]
17. Changes in short-term health-related quality of life in women undergoing gynecologic oncologic laparotomy: an associated factor analysis.
Minig L; Vélez JI; Trimble EL; Biffi R; Maggioni A; Jeffery DD
Support Care Cancer; 2013 Mar; 21(3):715-26. PubMed ID: 22930239
[TBL] [Abstract][Full Text] [Related]
18. Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?
Coomans MB; Dirven L; Aaronson NK; Baumert BG; Van Den Bent M; Bottomley A; Brandes AA; Chinot O; Coens C; Gorlia T; Herrlinger U; Keime-Guibert F; Malmström A; Martinelli F; Stupp R; Talacchi A; Weller M; Wick W; Reijneveld JC; Taphoorn MJB
Neuro Oncol; 2019 Nov; 21(11):1447-1457. PubMed ID: 31682733
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
20. Mental distress, quality of life and social support in recurrent ovarian cancer patients during active chemotherapy.
Wen Q; Shao Z; Zhang P; Zhu T; Li D; Wang S
Eur J Obstet Gynecol Reprod Biol; 2017 Sep; 216():85-91. PubMed ID: 28738296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
